Hyundai Pharmaceutical Co Ltd
KRX:004310
Hyundai Pharmaceutical Co Ltd
KRX:004310
Price:
9 180
KRW
3.49%
Market Closed
Market Cap:
₩239.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Hyundai Pharmaceutical Co Ltd
KRX:004310
|
KR |
Relative Value
The Relative Value of one
Hyundai Pharmaceutical Co Ltd
stock under the Base Case scenario is
6 245.67
KRW.
Compared to the current market price of 9 180 KRW,
Hyundai Pharmaceutical Co Ltd
is
Overvalued by 32%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
6 245.67
KRW
Overvaluation 32%
Multiples Across Competitors
Competitors Multiples
Hyundai Pharmaceutical Co Ltd Competitors
Hyundai Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
|
Hyundai Pharmaceutical Co Ltd
KRX:004310
|
239.9B KRW | 1.3 | 231.4 | 45.8 | 135.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
860.3B USD | 13.1 | 41.3 | 27.9 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.9B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.8 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.1B GBP | 4.9 | 28 | 15.6 | 22 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.3B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.5B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
